SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-045922
Filing Date
2022-08-09
Accepted
2022-08-09 16:32:07
Documents
60
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_protaratherap.htm   iXBRL 10-Q 1009112
2 CERTIFICATION f10q0622ex31-1_protara.htm EX-31.1 12644
3 CERTIFICATION f10q0622ex31-2_protara.htm EX-31.2 12564
4 CERTIFICATION f10q0622ex32-1_protara.htm EX-32.1 6109
  Complete submission text file 0001213900-22-045922.txt   4203182

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tara-20220630.xsd EX-101.SCH 51839
6 XBRL CALCULATION FILE tara-20220630_cal.xml EX-101.CAL 22257
7 XBRL DEFINITION FILE tara-20220630_def.xml EX-101.DEF 188408
8 XBRL LABEL FILE tara-20220630_lab.xml EX-101.LAB 397160
9 XBRL PRESENTATION FILE tara-20220630_pre.xml EX-101.PRE 200888
54 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_protaratherap_htm.xml XML 432110
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 221148855
SIC: 2836 Biological Products, (No Diagnostic Substances)